NASDAQ:IRD Opus Genetics Q3 2024 Earnings Report $3.98 -0.14 (-3.28%) As of 11:46 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Opus Genetics EPS ResultsActual EPS-$0.29Consensus EPS -$0.30Beat/MissBeat by +$0.01One Year Ago EPSN/AOpus Genetics Revenue ResultsActual Revenue$3.87 millionExpected Revenue$1.17 millionBeat/MissBeat by +$2.70 millionYoY Revenue GrowthN/AOpus Genetics Announcement DetailsQuarterQ3 2024Date11/12/2024TimeBefore Market OpensConference Call DateTuesday, November 12, 2024Conference Call Time9:00AM ETUpcoming EarningsOpus Genetics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Opus Genetics Earnings HeadlinesAnalysts Are Bullish on These Healthcare Stocks: Evaxion Biotech (EVAX), Opus Genetics (IRD)August 23 at 3:01 PM | theglobeandmail.comOpus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 19, 2026 | globenewswire.comA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money network by April 2027. BlackRock CEO Larry Fink already calls it 'the next major evolution in market infrastructure.' Our research has identified one small, overlooked position at the center of this policy-driven shift - already drawing quiet institutional buying from BNY Mellon, State Street, and JPMorgan. It currently trades for pennies relative to where institutional demand could push it. The Q3 2026 compliance deadline may be the last window before prices move.August 26 at 1:00 AM | Awesomely (Ad)Opus Genetics, Inc. (NASDAQ:IRD) Receives $10.69 Average Target Price from BrokeragesAugust 17, 2026 | americanbankingnews.comOpus Genetics (NASDAQ:IRD) Rating Increased to Hold at Wall Street ZenAugust 16, 2026 | americanbankingnews.comOpus Genetics Q3 EPS Raised by Brookline Capital MarketsAugust 15, 2026 | americanbankingnews.comSee More Opus Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email. Email Address About Opus GeneticsOpus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.View Opus Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles HONA: The Spin-Off Story the Market Is Reading WrongPDD Beat Earnings—So Why Did the Stock Still Fall?Marzetti Stock Confirms Reversal on Earnings Strength, Dividend GrowthDICK's Sporting Goods Faces Pain Now for a Bigger PrizeStoneX: Too Far Too Fast?Pathward’s Credit Scare Tests Its Comeback StoryNVIDIA Earnings Could Move These 3 AI Stocks—Here’s What to Watch Upcoming Earnings Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026)Autodesk (8/27/2026)Marvell Technology (8/27/2026)Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
